ASN Kidney Week 2023 Highlights Exciting Developments in Glomerular Diseases, ADPKD |
|
ASN Kidney Week 2023 was an exciting one for KDIGO, and not just for the opportunity to catch up with colleagues, meet new people, and explore Philadelphia. This year offered significant news in research and treatment of glomerular diseases (GD), with new trials reporting successful outcomes, and a number of new treatments on track to receive approval from regulatory authorities.
ASN Kidney Week also offered the opportunity to hear the latest in evaluating and treating patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) at the KDIGO Exhibitor Spotlight.
The news and insights from ASN Kidney Week came at an ideal time for KDIGO, which is currently updating the 2021 GD Guideline on a chapter-by-chapter basis under the leadership of Co-Chairs, Brad Rovin, MD (United States), and Jürgen Floege, MD (Germany). The KDIGO ADPKD Guideline, co-chaired by Olivier Devuyst, MD, (Switzerland), and Vicente Torres, MD (United States), is currently available for public review (see more on this below) and will be published in 2024.
|
|
Breakthroughs in Glomerular Diseases
When KDIGO published the 2021 GD Guideline, there were limited recommended treatment options, with no drugs approved for IgA Nephropathy (IgAN). The main course of treatment involved deciding whether to use systemic glucocorticoids and at what dose. There are now a number of promising new treatment options available, with more on the horizon.
Two drugs had accelerated approval for IgA in the last year. Both trials finished their Phase 3 follow-on study looking at kidney function after being approved on the basis of proteinuria, and both trials were successful. The first drug to gain approval was Nefecon and the second drug, Sparsentan, was recently approved by the FDA. There are several other drugs in various stages of development, with positive data also shared at ASN.
KDIGO sat down with Dr. Rovin at ASN Kidney Week to get his insights on the changing landscape in managing and treating glomerular diseases. "There is a lot of excitement about glomerular disease right now," said Dr. Rovin. "In the last several years we have had major advancements in the treatment of several glomerular diseases, with a great deal of new info on IgAN. We now have a very nicely defined pathway for clinical trial approach and drug approval through the FDA, which has really stimulated a lot of activity in the field to bring new drugs forward."
Dr. Rovin added, "The important thing the KDIGO GD Guideline Work Group will have to do is to assess the data out there. There is clearly a lot of exciting work ahead, and we will continue to revisit the latest science because the field is moving forward so quickly."
|
|
An Evening with KDIGO: Evaluation and Management of Patients with ADPKD
KDIGO held an ASN Exhibitor Spotlight event on Thursday, November 2, which included dinner and the opportunity to hear a panel of global experts discuss the latest science in evaluating and managing ADPKD.
The session was chaired by KDIGO Knowledge Translation Lead, Edgar Lerma, MD (United States), and featured ADPKD Guideline Co-Chair, Vicente Torres, MD (United States), Guideline Work Group Members Ron Perrone, MD (United States), and Gopi Rangan, MD, (Australia), as well as ADPKD patient and KDIGO CKD Guideline Work Group Member, Kelly Morrow (United States).
The speakers addressed important issues and topics discussed in the guideline draft, which is currently out for public review (see more on this below). Topics included: nomenclature, diagnosis, prognosis, prevalence, kidney manifestations, CKD management, kidney failure, kidney replacement therapy, delaying progression, polycystic liver disease, intracranial aneurysms and extrarenal manifestations, lifestyle and psychosocial aspects, pregnancy and reproductive issues, pediatric issues, and approaches to managing ADPKD.
"It was a pleasure to moderate this session at ASN Kidney Week 2023 and to hear the depth of insights shared by our exceptional speakers on the complexities of evaluating and treating ADPKD," said Dr. Lerma. "On behalf of KDIGO, I would like to thank both our speakers and the highly engaged attendees who made this exchange of knowledge so enriching. As we eagerly anticipate the publication of the KDIGO ADPKD Guideline, we hope the session marks a helpful stepping stone towards enhanced understanding and improved outcomes for patients with ADPKD."
|
|
Deadline Extended! KDIGO ADPKD Guideline Available for Public Review Through December 1 |
|
The deadline for feedback on the public review draft of the KDIGO ADPKD Guideline has been officially extended to December 1, 2023. We invite you to review this guideline and share your candid comments and suggestions. A final revised version will be prepared for publication based on the feedback received during this open comment period.
Each chapter has its own feedback survey link. Reviewers can focus exclusively on the chapter that pertains to their specific area of expertise, or they can review all chapters. Only completed surveys will be acknowledged. The chapters (with survey links embedded) include:
Survey links will close on December 1 at 12pm ET, so please ensure all feedback is submitted by that time.
|
|
Save the Date: ISN-KDIGO Webinar on Symptom-Based Complications in Dialysis
Tuesday, December 5, 7:00 AM (PT)/ 3:00 PM (GMT)
Save the date for the next ISN-KDIGO webinar on symptom-based complications in dialysis, on Tuesday, December 5, at 7:00 AM (PST)/ 3:00 PM (GMT). The webinar features the Co-Chairs from the KDIGO Symptom-Based Complications in Dialysis Controversies Conference, Raj Mehrotra, MD (United States), and Edwina Brown, MD (United Kingdom). The webinar also features conference attendee and patient, Dawn Edwards (United States). Stay tuned for more information on this exciting webinar in the coming weeks.
|
|
Systematic Review for the KDIGO 2022 Hepatitis C Guideline
The systematic review for the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease (CKD) is now available in The American Journal of Kidney Diseases (AJKD).
|
|
About KDIGO
KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve outcomes for people with kidney disease on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the people it serves.
|
|
|
|
|
|
|
